Hematologic malignancies and Li-Fraumeni syndrome.
Mahesh SwaminathanSarah A BannonMark RoutbortKiran NaqviTapan M KadiaKoichi TakahashiYesid AlvaradoFarhad Ravandi-KashaniKeyur P PatelRichard ChamplinHagop KantarjianLouise StrongCourtney D DiNardoPublished in: Cold Spring Harbor molecular case studies (2019)
Li-Fraumeni syndrome (LFS) is an autosomal dominant condition associated with a high risk of a broad range of childhood- and adult-onset cancers. LFS is related to germline mutations of the tumor-suppressor gene TP53 The most common reported leukemia associated with LFS is hypodiploid acute lymphoblastic leukemia, but myeloid malignancies including acute myeloid leukemia (AML), chronic myeloid leukemia, and myelodysplastic syndrome (MDS) are also reported, often in the setting of therapy-related disease. We reviewed the clinicopathologic characteristics including cytogenetics and molecular analysis for seven adult patients with LFS and hematologic malignancies evaluated at the Hereditary Hematologic Malignancy Clinic (HHMC) at MD Anderson Cancer Center. We present this LFS review series to increase awareness of LFS for the appropriate diagnosis of both patients and potentially affected relatives, as well as provide experience with patient outcomes in this difficult to treat population.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- chronic myeloid leukemia
- end stage renal disease
- ejection fraction
- bone marrow
- primary care
- case report
- chronic kidney disease
- peritoneal dialysis
- papillary thyroid
- stem cells
- copy number
- squamous cell carcinoma
- molecular dynamics
- patient reported outcomes
- genome wide
- squamous cell
- gene expression
- mesenchymal stem cells
- dna methylation
- solid state